Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2010 1
2011 1
2017 1
2018 2
2019 1
2020 3
2021 2
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.
Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benattar YD, Skiada A, Andini R, Eliakim-Raz N, Nutman A, Zusman O, Antoniadou A, Pafundi PC, Adler A, Dickstein Y, Pavleas I, Zampino R, Daitch V, Bitterman R, Zayyad H, Koppel F, Levi I, Babich T, Friberg LE, Mouton JW, Theuretzbacher U, Leibovici L. Paul M, et al. Among authors: pavleas i. Lancet Infect Dis. 2018 Apr;18(4):391-400. doi: 10.1016/S1473-3099(18)30099-9. Epub 2018 Feb 16. Lancet Infect Dis. 2018. PMID: 29456043 Clinical Trial.
Global Cutaneous Mucormycosis: A Systematic Review.
Skiada A, Drogari-Apiranthitou M, Pavleas I, Daikou E, Petrikkos G. Skiada A, et al. Among authors: pavleas i. J Fungi (Basel). 2022 Feb 16;8(2):194. doi: 10.3390/jof8020194. J Fungi (Basel). 2022. PMID: 35205948 Free PMC article. Review.
Epidemiology and Diagnosis of Mucormycosis: An Update.
Skiada A, Pavleas I, Drogari-Apiranthitou M. Skiada A, et al. Among authors: pavleas i. J Fungi (Basel). 2020 Nov 2;6(4):265. doi: 10.3390/jof6040265. J Fungi (Basel). 2020. PMID: 33147877 Free PMC article. Review.
Rare fungal infectious agents: a lurking enemy.
Skiada A, Pavleas I, Drogari-Apiranthitou M. Skiada A, et al. Among authors: pavleas i. F1000Res. 2017 Oct 31;6:1917. doi: 10.12688/f1000research.11124.1. eCollection 2017. F1000Res. 2017. PMID: 29152230 Free PMC article. Review.
Epidemiology of Mucormycosis in Greece; Results from a Nationwide Prospective Survey and Published Case Reports.
Drogari-Apiranthitou M, Skiada A, Panayiotides I, Vyzantiadis TA, Poulopoulou A, Christofidou M, Antoniadou A, Roilides E, Iosifidis E, Mamali V, Argyropoulou A, Sympardi S, Charalampaki N, Antonakos N, Mantzana P, Mastora Z, Nicolatou-Galitis O, Orfanidou M, Pana ZD, Pavleas I, Pefanis A, Sakka V, Spiliopoulou A, Stamouli M, Tofas P, Vagiakou E, Petrikkos G. Drogari-Apiranthitou M, et al. Among authors: pavleas i. J Fungi (Basel). 2023 Mar 29;9(4):425. doi: 10.3390/jof9040425. J Fungi (Basel). 2023. PMID: 37108880 Free PMC article.
In vivo fitness of carbapenem-resistant Acinetobacter baumannii strains in murine infection is associated with treatment failure in human infections.
Nutman A, Temkin E, Lellouche J, Rakovitsky N, Hameir A, Daikos G, Durante-Mangoni E, Pavleas I, Dishon Y, Petersiel N, Yahav D, Eliakim N, Bernardo M, Iossa D, Friberg LE, Theuretzbacher U, Leibovici L, Paul M, Carmeli Y; AIDA Study Group. Nutman A, et al. Among authors: pavleas i. Clin Microbiol Infect. 2022 Jan;28(1):73-78. doi: 10.1016/j.cmi.2021.05.005. Epub 2021 May 11. Clin Microbiol Infect. 2022. PMID: 33984488
Colistin Resistance Development Following Colistin-Meropenem Combination Therapy Versus Colistin Monotherapy in Patients With Infections Caused by Carbapenem-Resistant Organisms.
Dickstein Y, Lellouche J, Schwartz D, Nutman A, Rakovitsky N, Dishon Benattar Y, Altunin S, Bernardo M, Iossa D, Durante-Mangoni E, Antoniadou A, Skiada A, Deliolanis I, Daikos GL, Daitch V, Yahav D, Leibovici L, Rognås V, Friberg LE, Mouton JW, Paul M, Carmeli Y; AIDA Study Group. Dickstein Y, et al. Clin Infect Dis. 2020 Dec 17;71(10):2599-2607. doi: 10.1093/cid/ciz1146. Clin Infect Dis. 2020. PMID: 31758195 Clinical Trial.
Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity.
Daitch V, Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benattar YD, Skiada A, Andini R, Eliakim-Raz N, Nutman A, Zusman O, Antoniadou A, Cavezza G, Adler A, Dickstein Y, Pavleas I, Zampino R, Bitterman R, Zayyad H, Koppel F, Zak-Doron Y, Levi I, Babich T, Turjeman A, Ben-Zvi H, Friberg LE, Mouton JW, Theuretzbacher U, Leibovici L. Daitch V, et al. Among authors: pavleas i. BMC Infect Dis. 2021 Mar 31;21(1):309. doi: 10.1186/s12879-021-05995-y. BMC Infect Dis. 2021. PMID: 33789574 Free PMC article.
Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial.
Dickstein Y, Lellouche J, Ben Dalak Amar M, Schwartz D, Nutman A, Daitch V, Yahav D, Leibovici L, Skiada A, Antoniadou A, Daikos GL, Andini R, Zampino R, Durante-Mangoni E, Mouton JW, Friberg LE, Dishon Benattar Y, Bitterman R, Neuberger A, Carmeli Y, Paul M; AIDA Study Group. Dickstein Y, et al. Clin Infect Dis. 2019 Aug 16;69(5):769-776. doi: 10.1093/cid/ciy988. Clin Infect Dis. 2019. PMID: 30462182 Clinical Trial.
Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes.
Nutman A, Lellouche J, Temkin E, Daikos G, Skiada A, Durante-Mangoni E, Dishon-Benattar Y, Bitterman R, Yahav D, Daitch V, Bernardo M, Iossa D, Zusman O, Friberg LE, Mouton JW, Theuretzbacher U, Leibovici L, Paul M, Carmeli Y; AIDA Study Group. Nutman A, et al. Clin Microbiol Infect. 2020 Sep;26(9):1185-1191. doi: 10.1016/j.cmi.2020.03.035. Epub 2020 Apr 3. Clin Microbiol Infect. 2020. PMID: 32251844 Free article. Clinical Trial.
13 results